Abnormal lipid profiles on fibrate derivatives.
作者信息
McLeod A J, Warren R J, Armitage M
出版信息
Lancet. 1996 Jan 27;347(8996):261. doi: 10.1016/s0140-6736(96)90436-5.
PMID:8551900
Abstract
摘要
相似文献
1
Abnormal lipid profiles on fibrate derivatives.贝特类衍生物的血脂异常情况。
Lancet. 1996 Jan 27;347(8996):261. doi: 10.1016/s0140-6736(96)90436-5.
2
Lipid profiles on fibric-acid derivatives.纤维酸衍生物的血脂谱
Lancet. 1994 Sep 3;344(8923):684-5.
3
Ciprofibrate and lipid profile.环丙贝特与血脂谱。
Lancet. 1994 Jul 9;344(8915):128-9. doi: 10.1016/s0140-6736(94)91314-5.
4
Statin + fibrate combination therapy fluvastatin with bezafibrate or ciprofibrate in high risk patients with vascular disease.他汀类药物与贝特类药物联合治疗：氟伐他汀与苯扎贝特或环丙贝特用于血管疾病高危患者。
Int J Cardiol. 1999 Jun 1;69(3):237-44. doi: 10.1016/s0167-5273(99)00013-3.
5
Impressive lipid changes following hypolipidaemic drug administration can unveil subclinical hyperthyroidism.
Diabetes Obes Metab. 2001 Apr;3(2):97-8. doi: 10.1046/j.1463-1326.2001.00133.x.
6
7
Comparative efficacy and safety of ciprofibrate and sustained-release bezafibrate in patients with type II hyperlipidaemia.环丙贝特与缓释苯扎贝特治疗II型高脂血症患者的疗效和安全性比较
Postgrad Med J. 1996 Dec;72(854):739-43. doi: 10.1136/pgmj.72.854.739.
8
Differential associations of statin and fibrate treatment with carotid arterial remodeling.他汀类药物和贝特类药物治疗与颈动脉重塑的差异关联。
Am J Hypertens. 2005 Nov;18(11):1476-81. doi: 10.1016/j.amjhyper.2005.05.019.
9
Biliary lipids, lithogenic index and biliary drug concentrations during etofibrate and bezafibrate treatment.益多酯和苯扎贝特治疗期间的胆汁脂质、成石指数及胆汁药物浓度
Eur J Drug Metab Pharmacokinet. 1995 Apr-Jun;20(2):113-8. doi: 10.1007/BF03226364.
10
Fibrate-induced increase in blood urea and creatinine.贝特类药物引起的血尿素和肌酐升高。
Nephrol Dial Transplant. 2001 Jul;16(7):1515. doi: 10.1093/ndt/16.7.1515.
Zotero 插件